menu
    • menu
    [{"orgOrder":0,"company":"Xellia Pharmaceuticals ApS","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Phenylephrine Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Xellia Pharmaceuticals ApS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xellia Pharmaceuticals ApS \/ Xellia Pharmaceuticals ApS","highestDevelopmentStatusID":"15","companyTruncated":"Xellia Pharmaceuticals ApS \/ Xellia Pharmaceuticals ApS"},{"orgOrder":0,"company":"Xellia Pharmaceuticals ApS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Vancomycin HCl","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Xellia Pharmaceuticals ApS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xellia Pharmaceuticals ApS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Xellia Pharmaceuticals ApS \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Xellia Pharmaceuticals ApS

    Menu

    Xellia Pharmaceuticals ApS

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Xellia Pharmaceuticals ApS

                            Denmark arrow
                            BOS Manchester
                            Not Confirmed

                            Xellia Pharmaceuticals ApS

                            Denmark arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vancomycin HCl

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Xellia Pharmaceuticals expands approved doses of VANCO READY™ (Ready-to-use Premixed Vancomycin bags)

                            Details : Xellia Pharmaceuticals has received approval for 3 additional dosages of VANCO READY™, expanding its range of room-temperature-stable, ready-to-use (RTU) Vancomycin injection premix bags.

                            Product Name : Vanco Ready

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            September 02, 2020

                            Lead Product(s) : Vancomycin HCl

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Xellia Pharmaceuticals ApS

                            Denmark arrow
                            BOS Manchester
                            Not Confirmed

                            Xellia Pharmaceuticals ApS

                            Denmark arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Phenylephrine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Eton Pharmaceuticals and Xellia Pharmaceuticals Announce Biorphen® (phenylephrine HCl) Co-Promotion Agreement

                            Details : Agreement significantly expands biorphen commercial footprint and provides access to institutions that prefer ready-to-use injectable formulations.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 21, 2020

                            Lead Product(s) : Phenylephrine Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Eton Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth